secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269538
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome Q3 net loss $57.5M; cash $272.6M; varegacestat data due by year-end
----------------------------------------------------------------------------

- Net loss of $57.5M for Q3 2025; cash and equivalents $272.6M.
- Expects topline data from Phase 3 RINGSIDE (varegacestat) before end of 2025.
- IM-1021 shows objective responses in B-cell lymphoma; initial data in 2026.
- HC74 payload overcomes multi-drug resistance in preclinical models.
- Cash runway into 2027; three preclinical ADCs targeting 2026 IND submissions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000119312525269538/0001193125-25-269538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000119312525269538/imnm-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer